NextCell Pharma AB
Develops cell therapies for autoimmune diseases and operates a private stem cell bank.
NXTCL | ST
Overview
Corporate Details
- ISIN(s):
- SE0009723125 (+1 more)
- LEI:
- 549300PBFGB5JYKXGA45
- Country:
- Sweden
- Address:
- Hälsovägen 7, 141 57 Huddinge
- Website:
- https://nextcellpharma.com/
- Sector:
- Manufacturing
Description
NextCell Pharma AB is a biopharmaceutical company developing advanced cell therapies for autoimmune diseases. Its lead drug candidate, ProTrans, is a novel stromal cell therapy in Phase II clinical trials for the treatment of type 1 diabetes. ProTrans is based on a patented technology platform for selecting and manufacturing potent cell products. In addition to its therapeutic development, NextCell operates Cellaviva, a private stem cell bank that provides services for the collection and storage of umbilical cord blood and tissue stem cells for future medical use. The company leverages its expertise in advanced cell handling, processing, and logistics for its clinical projects and collaborative services.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all NextCell Pharma AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NextCell Pharma AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NextCell Pharma AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
